Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. - Wikidata - awgldk - TriplyDB

Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.

Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.

http://www.wikidata.org/entity/Q43693338

about

Neurophysiological basis of rapid eye movement sleep behavior disorder: informing future drug development Functional neuroimaging in Parkinson's disease Manganese neurotoxicity: new perspectives from behavioral, neuroimaging, and neuropathological studies in humans and non-human primates The effect of Parkinson's disease on interference control during action selection.Neuroimaging in Parkinson disease: from research setting to clinical practice.Human gene therapy and imaging in neurological diseases.Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease.Parkinson subtypes progress differently in clinical course and imaging pattern Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts.A dual-tracer study of extrastriatal 6-[18F]fluoro-m-tyrosine and 6-[18F]-fluoro-L-dopa uptake in Parkinson's disease.Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease The role of molecular imaging in the diagnosis and management of neuropsychiatric disorders.Do dopamine agonists or levodopa modify Parkinson's disease progression?Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.Aberrant functional connectivity within the basal ganglia of patients with Parkinson's disease Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease Functional imaging in Parkinson's disease and dementia with Lewy bodies.Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders.Premotor Parkinson's disease: concepts and definitions Positron emission tomography and single-photon emission computed tomography in central nervous system drug development.Neural correlates underlying micrographia in Parkinson's disease.Putaminal Diffusivity Correlates With Disease Progression in Parkinson's Disease: Prospective 6-Year Study Molecular imaging in hereditary forms of parkinsonism.Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum.Molecular imaging as a guide for the treatment of central nervous system disorders The search for biomarkers in Parkinson's disease: a critical review.PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches.Development of Parkinson's disease biomarkers.PET/CT in diagnosis of movement disorders.Functional neuroimaging in Parkinson's disease.The role of the putamen in language: a meta-analytic connectivity modeling study.New insights on the mitochondrial proteome plasticity in Parkinson's disease.Position Emission Tomography/Single-Photon Emission Tomography Neuroimaging for Detection of Premotor Parkinson's Disease.A novel adaptive discrete cosine transform-domain filter for gap-inpainting of high resolution PET scanners.(18)F-DOPA PET with and without MRI fusion, a receiver operator characteristics comparison Improved dopamine transporter binding activity after bone marrow mesenchymal stem cell transplantation in a rat model of Parkinson's disease: small animal positron emission tomography study with F-18 FP-CIT.Spatial remapping of cortico-striatal connectivity in Parkinson's disease.Discrimination and categorization of emotional facial expressions and faces in Parkinson's disease.Effect of tetrabenazine on the striatal uptake of exogenous L-DOPA in vivo: a PET study in young and aged rhesus monkeys.

P2860

Q26749275-3620FA87-7594-4491-B7A5-45A818452A20 Q27013767-6D0BAD47-D182-489F-9AE0-2276610F2796 Q28384717-30FE8E94-384F-4C67-9C0C-8F1B3288B929 Q30371505-1DED1B20-563F-4414-B107-62A57B60686C Q30868628-B5BD05E5-C448-4295-AE97-3E2F6DF4F630 Q31023442-E13623FA-BBFC-4B21-8A6C-1E8CF85A1BEF Q34416128-718666A7-C5CB-4F9E-B136-456917F38242 Q34442161-AA33D7F0-C49A-4494-8E64-539850CFA8F6 Q34554452-1CCC37B0-3801-48F9-B9D5-0441FDC50E07 Q34825634-034A051D-0856-4FBC-9A7E-237FA46A3312 Q34827117-EFAA5FF5-5A1B-4FA4-9984-75AE096A46FB Q34897526-AE5BF8B0-CC82-45B0-A533-4002438004B8 Q35015794-2A0CFFE4-BCE2-421D-B3FF-9D1F12BAA86C Q35649302-778C57B1-ECFB-41E7-8BC7-2F4084FB25CE Q35752869-A145D61F-2D31-49FE-8E40-EE1ED655ED6A Q35759065-8D6AC42B-E910-40D5-850D-C64219F2A979 Q35846770-28AFC1AF-9525-4EE2-B800-E6BF2CAA4C47 Q35863417-5CC3C5C7-54DE-4C6A-A26D-8475E60CBABF Q35910290-8175B49B-2289-4413-A0E2-08E3F353143C Q35910731-1DC8F00B-D045-4948-98C6-6D121272D9B6 Q36129732-EF1994B1-FE37-4DD4-9A39-866E92C98CA0 Q36481742-9A31E555-4094-47A0-8B88-2D1E3B601232 Q36580852-03823637-903E-4057-B7FC-50B1A036CA5D Q36771898-45FFE483-6745-44B4-8C9F-D285E1F6A795 Q37076753-67010278-05DA-4981-95A8-46786FDEFB03 Q37262953-BCEEE2F5-6B1E-4B13-BF67-1670CC315E36 Q37352054-D0371C31-66E0-4779-BDD0-BB9AFEB3462E Q37606115-71E35C33-6D01-48A2-8A44-25F8225C2BA2 Q37810992-4870B007-E169-4704-A492-9E69D8DAF37C Q37896142-A43ECCD8-597F-4CB0-B1D1-33FF03AF0270 Q38088371-ED09EC05-EDF4-4065-A3C4-F0737903421D Q38375992-81818902-3DF4-42C9-B0B6-8302C02F8BF6 Q38452561-26FA56EF-8F8E-4D5F-8553-AB87E34653ED Q38699508-C3006054-5B35-43AE-9F6D-94367E23CDFC Q40212014-E913B444-E057-4C03-A647-F563D27E64E0 Q41627302-85D7A9D3-B610-4620-99A4-C3805D61C6C2 Q42470263-507C9B43-D886-4CFC-93A2-DCF02AD72104 Q43285295-55D9E784-4017-435E-AC2D-D2C2BD67524E Q43773609-80ADEEFC-1385-4700-BB8E-D97E7C73D904 Q43976825-BCFC04B2-E251-4CB5-961F-320627BB8EC1

P2860

Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.

http://www.wikidata.org/entity/Q43693338

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.

@en

Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.

@nl

type

label

Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.

@en

Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.

@nl

prefLabel

Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.

@en

Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.

@nl

P1433

Q43693338-26871C74-B220-4D3E-9761-196613EB5A7D

P1476

Q43693338-BA066266-899C-4353-BD06-B9CD70065045

P2093

Q43693338-35B526A4-EF4A-4DB8-AB65-9023A23922E4

Q43693338-38C72EE7-7E0C-4367-9657-D825A5B71882

Q43693338-539C73DD-A8FB-4084-8077-F414BF1E2201

Q43693338-6B9351EC-F709-432F-B18F-4D699B091987

Q43693338-7321A2FA-1894-4AF5-AFE6-1368B8DD1E18

Q43693338-A7D5A857-34A8-4E80-9F60-D29C2E6658D4

Q43693338-D40EC0F3-4205-4C03-87EB-49C9E5E70041

P2860

Q43693338-11CDF5AD-06A9-47A5-84FC-B17943F631E5

Q43693338-13B76F67-DBAB-4F0E-8A7C-7FDC5F79914E

Q43693338-3580D13F-ED1C-4D6F-9F4A-C47A578FA11B

Q43693338-40A022F2-1E45-4354-9B16-DA75BC6ADE5F

Q43693338-463FF848-008E-4615-9A50-A911974AE59F

Q43693338-4C5BC897-9F9E-4A34-A00E-F5221C0A519F

Q43693338-4E468AD3-B2C6-4BCA-A58B-FF1F6D260DF8

Q43693338-564E23A8-965B-4944-AD4C-906DCC0F9BA8

Q43693338-5CF124AC-17F2-4E08-B31C-C6A0EB7A79AB

Q43693338-71AA3601-F4BE-4306-B68C-7C1A43713D71

P304

Q43693338-6927E1A8-D281-43ED-84DD-B6F19A76DD56

P31

Q43693338-C4DC1494-6EBE-4BE9-89E4-F9FE053BC29B

P356

Q43693338-C5AF64E2-2889-4915-9043-EFDAB956B04B

P407

Q43693338-885D0FED-0D2F-442C-9E7C-BBA7EB82E1EE

P433

Q43693338-25FA5332-E53D-4EFD-9D63-580F38246DC8

P478

Q43693338-42E6DC01-2014-4376-81B9-5088593719F4

P577

Q43693338-01084026-5885-4DC0-8C0D-107C64E2FC21

P698

Q43693338-644B00AB-D6B7-4A1C-AB17-A2BC0E6329F9

P921

Q43693338-F3163B26-3F4B-4716-B840-DDAF711CE03B

P356

P1433

Movement Disorders

P1476

Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.

@en

P2093

Bergman J

http://www.w3.org/2001/XMLSchema#string

Haaparanta M

http://www.w3.org/2001/XMLSchema#string

Nurmi E

http://www.w3.org/2001/XMLSchema#string

Rinne JO

http://www.w3.org/2001/XMLSchema#string

Ruottinen HM

http://www.w3.org/2001/XMLSchema#string

Solin O

http://www.w3.org/2001/XMLSchema#string

Sonninen P

http://www.w3.org/2001/XMLSchema#string

P2860

Ageing and Parkinson's disease: substantia nigra regional selectivity

[18F]fluorodopa PET shows striatal dopaminergic dysfunction in juvenile neuronal ceroid lipofuscinosis.

Change in lateralization of the P22/N30 cortical component of median nerve somatosensory evoked potentials in patients with cervical dystonia after successful treatment with botulinum toxin A.

Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow.

Age-dependent decline of nigrostriatal dopaminergic function: a positron emission tomographic study of grandparents and their grandchildren.

Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism.

Functional imaging in relation to parkinsonian syndromes.

The response to levodopa in Parkinson's disease: imposing pharmacological law and order.

The natural history of Parkinson's disease.

Nigrostriatal function in humans studied with positron emission tomography.

P304

608-615

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.1139

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2001-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11481683

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease